Gastroenterologie
a hepatologie

Serum zymogen glycoprotein 2 antibodies (anti-GP2) in patients with inflammatory bowel disease

Karin Malíčková ^{Orcid.org  1,2}, Dana Ďuricová ^{Orcid.org  1}, Martin Bortlík ^{Orcid.org  1,3,4}, Luděk Hrdlička ^{Orcid.org  5,6}, Naděžda Machková ^{Orcid.org  1}, Milan Lukáš ^{Orcid.org  1}

+ Affiliation
¹ IBD clinical and research centre ISCARE a.s., Prague, Czech Republic
² Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
³ Department of Internal Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
⁴ Institute of Pharmacology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
⁵ Gastroenterologie, Poliklinika Budějovická, Medicon a. s., Praha
⁶ Chirurgické oddělení, NH Hospital a.s., Nemocnice Hořovice

Summary

Purpose of the study: The aim of the study is to examine the incidence and significance of serum antibodies against zymogen glycoprotein 2 (anti-GP2) in patients with inflammatory bowel disease (IBD).

Methods: Eighty-one patients with IBD were examined, 66 patients with Crohn's disease (CD) and 15 with ulcerative colitis (UC); there was also a control group of 20 patients with untreated coeliac disease and 50 healthy blood donors. All examined patients with IBD were treated with infliximab. Analyses of anti-GP2 IgG/lgA were performed in samples from week 0 (W0) and week 10 (W10) of the treatment.

Results: Anti-GP2 in at least one isotype were found in 52% of patients with CD, but only in 13% of patients with UC (p = 0.007). In both control groups, the incidence of anti-GP2 was minimal. Compared to UC patients, individuals with CD achieved significantly higher concentrations of anti-GP2 (p = 0.001 for anti-GP2 IgG at W0 and p < 0.001 for anti-GP2 IgA at W0). No significant changes in concentrations of auto-antibodies were observed during 10 weeks of the biological treatment. No evidence of anti-GP2 IgG/lgA association with gender, age, location or type of IBD, or with the activity of the disease was proven. The only significant correlation was found in anti-GP2 IgA with CD damage when stricturing and fistulizing form was related to more frequent incidence and higher anti-GP2 IgA titres.

Conclusions: Anti-GP2 occure in approximately half of patients with CD. The incidence of anti-GP2 does not correlate with CD location, form or type of the alimentary tract damage; it is not related to the disease activity and concentrations of autoantibody concentrations do not change significantly during the IBD biological treatment.

Keywords

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users